First Australian site joins AstraZeneca’s phase 3 breast cancer trial

Australia’s first site joins an international breast cancer clinical trial aimed at determining whether AstraZeneca’s next-gen hormone treatment can provide a more effective therapy than current standards.

The CAMBRIA-2 trial targets men and women with ER-positive, HER2-negative early breast cancer who face an intermediate or high risk of recurrence. This Phase III study of camizestrant – a selective oestrogen degrader (SERD) – seeks to enrol 5,500 patients across 700 sites in 40 countries.

Dr Nick Zdenkowski, a medical oncologist at Lake Macquarie Private Hospital and the principal investigator for the trial, emphasised the significance of this research.

“We need better treatments to stop breast cancer recurrence and death,” Dr Zdenkowski said. “I hope this trial will show that the new drug is both more effective and has fewer side effects than the current standard of care, ultimately leading to reductions in breast cancer recurrences and deaths worldwide.”

Highlighting the broader importance of medical research, Dr Zdenkowski explained that progress in science and collaboration is essential for improving health outcomes.

“The ability to create new knowledge through scientific rigour and collaboration is an exciting process,” he said. “CAMBRIA-2 brings hope to participants that they can contribute to improved outcomes for all current and future patients, and potentially for themselves.”

Dr Zdenkowski also expressed pride in the hospital’s pioneering role, as the first Australian site to be activated and to recruit the first patient for the study.

“It shows the dedication of all the people involved, and the effective processes that are in place to allow trials to start up in as short a timeframe as possible to bring this sought-after option to the patients who we look after,” he said. “We now have the opportunity to contribute to practice change and potentially improve patient outcomes worldwide.”

Hollie Ritchie, Manager of Ramsay Health Care’s Lake Macquarie Private Hospital’s Clinical Trials and Research Unit, echoed Dr Zdenkowski’s sentiments, proud to be part of such an important initiative.

“We have already recruited seven participants, which shows how important it is to have clinical trial options available to our patients,” Ritchie said. “At Lake Macquarie Private Hospital, we’re committed to offering patients the best available treatments close to home, whether that be the best standard of care or a new treatment that has the potential to be more effective.

“For our people and our patients, it’s wonderful knowing we are helping to better standardise practice and contribute to improved treatments and outcomes for future patients worldwide.”

In reimagining healthcare, Health Industry Hub^TM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.